Laurion Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.19M | Buy |
+36,100
| New | +$2.1M | 0.1% | 202 |
|
|
2024
Q3 | – | Sell |
-9,507
| Closed | -$395K | – | 324 |
|
|
2024
Q2 | $395K | Sell |
9,507
-1,666,076
| -99% | -$74.5M | ﹤0.01% | 382 |
|
|
2024
Q1 | $90.9M | Buy |
1,675,583
+248,986
| +17% | +$12.7M | 0.77% | 25 |
|
|
2023
Q4 | $73.2M | Buy |
1,426,597
+423,255
| +42% | +$22.2M | 0.62% | 42 |
|
|
2023
Q3 | $58.2M | Buy |
1,003,342
+160,013
| +19% | +$9.8M | 0.36% | 66 |
|
|
2023
Q2 | $53.9M | Buy |
+843,329
| New | +$56.6M | 0.3% | 70 |
|
|
2022
Q4 | – | Sell |
-570
| Closed | -$41K | – | 426 |
|
|
2022
Q3 | $41K | Buy |
+570
| New | +$41.3K | ﹤0.01% | 456 |
|
|
2022
Q1 | – | Sell |
-17,935
| Closed | -$1.2M | – | 549 |
|
|
2021
Q4 | $1.12M | Sell |
17,935
-171,600
| -91% | -$10.1M | 0.01% | 338 |
|
|
2021
Q3 | $11.2M | Buy |
189,535
+182,945
| +2,776% | +$12M | 0.05% | 257 |
|
|
2021
Q2 | $440K | Buy |
+6,590
| New | +$430K | ﹤0.01% | 530 |
|
|
2021
Q1 | – | Sell |
-872,140
| Closed | -$54.1M | – | 748 |
|
|
2020
Q4 | $54.1M | Buy |
872,140
+316,954
| +57% | +$19.5M | 0.42% | 52 |
|
|
2020
Q3 | $33.5M | Buy |
555,186
+149,004
| +37% | +$8.97M | 0.4% | 57 |
|
|
2020
Q2 | $23.9M | Sell |
406,182
-2,746,144
| -87% | -$164M | 0.27% | 103 |
|
|
2020
Q1 | $176M | Buy |
+3,152,326
| New | +$193M | 1.91% | 10 |
|
|
2019
Q3 | – | Sell |
-297,366
| Closed | -$14M | – | 1022 |
|
|
2019
Q2 | $13.5M | Buy |
297,366
+265,233
| +825% | +$12.4M | 0.13% | 160 |
|
|
2019
Q1 | $1.53M | Buy |
32,133
+9,952
| +45% | +$496K | 0.02% | 443 |
|
|
2018
Q4 | $1.15M | Buy |
22,181
+21,430
| +2,854% | +$1.15M | 0.02% | 522 |
|
|
2018
Q3 | $47K | Sell |
751
-22,516
| -97% | -$1.34M | ﹤0.01% | 1117 |
|
|
2018
Q2 | $1.29M | Buy |
+23,267
| New | +$1.26M | 0.01% | 712 |
|
|
2018
Q1 | – | Sell |
-237,748
| Closed | -$15.3M | – | 1348 |
|
|
2017
Q4 | $14.6M | Buy |
237,748
+227,748
| +2,277% | +$14.2M | 0.07% | 268 |
|
|
2017
Q3 | $637K | Sell |
10,000
-47,999
| -83% | -$2.8M | ﹤0.01% | 1087 |
|
|
2017
Q2 | $3.23M | Sell |
57,999
-153,739
| -73% | -$8.37M | 0.02% | 653 |
|
|
2017
Q1 | $11.5M | Buy |
211,738
+209,038
| +7,742% | +$11.5M | 0.09% | 244 |
|
|
2016
Q4 | $158K | Buy |
+2,700
| New | +$148K | ﹤0.01% | 1033 |
|
|
2015
Q4 | – | Sell |
-800
| Closed | -$47K | – | 884 |
|
|
2015
Q3 | $47K | Buy |
+800
| New | +$50.8K | ﹤0.01% | 706 |
|
|
2013
Q4 | – | Sell |
-200
| Closed | -$10.2K | – | 215 |
|
|
2013
Q3 | $9K | Buy |
+200
| New | +$8.78K | ﹤0.01% | 163 |
|
Other funds holding BMY
VCM
VPM
Laurion Capital Management's BMY Position: Q1 2026 in Review
Laurion Capital Management opened a new position in Bristol-Myers Squibb (BMY) in Q1 2026: 36,100 shares worth $2.19M. The stake represents 0.1% of the portfolio and ranks #202 among its holdings. This is a return to the name: Laurion Capital Management previously reported a position in BMY as recently as Q2 2024.
Laurion Capital Management first reported a position in BMY in Q3 2013 and has held it in 26 quarters since. The position peaked at $176M in Q1 2020. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Laurion Capital Management held 36,100 shares of Bristol-Myers Squibb worth $2.19M as of Q1 2026.
- Bristol-Myers Squibb was a new Laurion Capital Management position in Q1 2026.
- Bristol-Myers Squibb made up 0.1% of Laurion Capital Management's portfolio in Q1 2026, its #202 holding.
- Laurion Capital Management first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 26 quarters since.
- Laurion Capital Management's Bristol-Myers Squibb position peaked at $176M in Q1 2020.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.